EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of acute hemodynamic effects and pharmacokinetic behavior of ibopamine in patients with severe heart failure


Arzneimittel-Forschung 36(2A): 349-354
Evaluation of acute hemodynamic effects and pharmacokinetic behavior of ibopamine in patients with severe heart failure
The aim of the present investigation was to evaluate the acute hemodynamic effects of a single oral dose of 200 mg ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine (epinine) in 11 patients with congestive heart failure (CHF) and to compare the influence of dopamine infusion and oral ibopamine on left ventricular function. Free and conjugated epinine plasma levels were also investigated in these patients and in a group of healthy volunteers to evaluate the correlation between epinine plasma levels and hemodynamic effects. The oral administration of 200 mg ibopamine to patients with CHF, increased cardiac index (+35%) and reduced peripheral and pulmonary vascular resistance (-29% and -26%) without modifying heart rate and systemic or pulmonary arterial pressure. The hemodynamic effect reached its maximum at about 90 min and was still present at 240 min. Ibopamine at a dose of 200 mg elicited similar effects to those observed with dopamine, 2-4 .mu.g/kg/min. The pharmacokineic behaviour of ibopamine in these patients was similar to that observed in a group of healthy volunteers. Free epinine plasma levels peaked at 30-60 min and decreased rapidly, thus showing a shorter time course than the hemodynamic effects.


Accession: 005395932

PMID: 3707648



Related references

Evaluation of acute hemodynamic effects and pharmacokinetic behaviour of ibopamine in patients with severe heart failure. Arzneimittel-Forschung 36(2a): 349-354, 1986

Acute hemodynamic effects of ibopamine in patients with severe congestive heart failure. British Journal of Clinical Pharmacology 19(5): 613-618, 1985

Acute hemodynamic effects of ibopamine, captopril, and placebo in patients with severe heart failure. Arquivos Brasileiros de Cardiologia 64(4): 335-339, 1995

Acute hemodynamic and short term effects of ibopamine in severe congestive heart failure. European Heart Journal 10(ABSTR SUPPL): 75, 1989

Acute and chronic effects of a new oral inotropic agent, ibopamine hydrochloride, on hemodynamic and metabolic responses to ergometer exercise in patients with severe congestive heart failure. Kokyu to Junkan. Respiration & Circulation 37(7): 773-778, 1989

Hemodynamic evaluation of ibopamine in severe congestive heart failure. European Journal of Clinical Pharmacology 26(1): 19-22, 1984

Hemodynamic evaluation during exercise test after acute and chronic ibopamine treatment in patients with congestive heart failure. Arzneimittel-Forschung 36(2a): 366-370, 1986

Acute haemodynamic effects of ibopamine in patients with severe congestive heart failure. British Journal of Clinical Pharmacology 19(5): 613-618, 1985

Acute haemodynamic effects of ibopamine and epinine in patients with severe heart failure. European Heart Journal 16(ABSTR SUPPL ): 157, 1995

Acute haemodynamic effects of ibopamine, captopril and placebo at rest and during exercise in patients with severe congestive heart failure. European Heart Journal 15(ABSTR SUPPL ): 200, 1994